Pharma Mar, S.A.
Pharma Mar, S.A. (PHMMF) Revenue
Annual & quarterly revenue history · segment & region breakdown
PHMMF · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsPharma Mar, S.A. trailing twelve-month (TTM) revenue is $0.23B, an increase of 26.57% year-over-year from $0.22B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.22B | +$0.05B | +26.57% |
| 2024-12-31 | $0.17B | +$0.02B | +10.56% |
| 2023-12-31 | $0.16B | -$0.04B | -19.45% |
| 2022-12-31 | $0.20B | -$0.03B | -14.57% |
| 2021-12-31 | $0.23B | -$0.04B | -14.87% |
| 2020-12-31 | $0.27B | +$0.18B | +214.57% |
| 2019-12-31 | $0.09B | -$0.08B | -47.08% |
| 2018-12-31 | $0.16B | -$0.02B | -9.58% |
| 2017-12-31 | $0.18B | -$0.00B | -0.89% |
| 2016-12-31 | $0.18B | -$0.01B | -6.16% |
Compare revenue vs peers
BiotechnologyCompare PHMMF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Pharma Mar, S.A. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Pharma Mar, S.A. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in EUR.
Data sourced from Pharma Mar, S.A.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
PHMMF revenue · 4 questionsPHMMF's trailing twelve-month (TTM) revenue is $0.23B. That is an increase of 26.57% year-over-year from $0.22B in FY2025.
▸ Source: FMP · Pharma Mar, S.A. SEC filings · GAAP · Pharma Mar, S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026